Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Adrián Segura-Díaz"'
Autor:
María Nieves Saez Perdomo, Ruth Stuckey, Elena González-Pérez, Santiago Sánchez-Sosa, Paula Estupiñan-Cabrera, Sunil Lakhwani Lakhwani, José David González San Miguel, Nuria Hernanz Soler, Marina Gordillo, Gloria González Brito, María Tapia-Torres, Ana Ruano, Adrián Segura-Díaz, Hugo Luzardo, Cristina Bilbao-Sieyro, María Teresa Gómez-Casares
Publikováno v:
Hematology Reports, Vol 16, Iss 1, Pp 140-150 (2024)
Background: Second- and third-generation tyrosine kinase inhibitors (TKIs) are now available to treat chronic-phase chronic myeloid leukemia (CP-CML) in the first and second line. However, vascular adverse events (VAEs) have been reported for patient
Externí odkaz:
https://doaj.org/article/dc6e5c75fbd04bd2b5703f7bc863f566
Autor:
Gómez-Casares, Ruth Stuckey, Adrián Segura-Díaz, María Nieves Sáez Perdomo, Manuel Mateo Pérez Encinas, Jóse David González San Miguel, Yanira Florido, Santiago Sánchez-Sosa, Juan Francisco López-Rodríguez, Cristina Bilbao-Sieyro, María Teresa
Publikováno v:
Cancers; Volume 15; Issue 13; Pages: 3384
For chronic myeloid leukemia (CML) patients with a known risk of cardiovascular events (CVE), imatinib is often recommended for first-line tyrosine kinase inhibitor (TKI) treatment rather than a second-generation TKI (2G-TKI) such as nilotinib or das
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::d2ea9764e08bcacf6eec1d15a49271eb
Autor:
Lucía Pérez-Lamas, Alejandro Luna, Concepción Boque, Blanca Xicoy, Pilar Giraldo, Raúl Pérez López, Concepción Ruiz Nuño, Natalia De las Heras, Elvira Mora Casterá, Javier López Marín, Adrián Segura Díaz, Valle Gómez, Patricia Vélez Tenza, Magdalena Sierra Pacho, Juan Antonio Vera Goñi, Melania Moreno Vega, Alberto Alvarez-Larrán, Montse Cortés, Manuel Pérez Encinas, Patricia Carrascosa Mastell, Anna Angona, Ana Rosell, Sunil Lakhwani, Mercedes Colorado, Elena Ramila, Carlos Cervero, Beatriz Cuevas, Lucía Villalón Blanco, Raquel de Paz, Antonio Paz Coll, María José Fernández, Luis Felipe Casado, Juan Manuel Alonso-Domínguez, María Magdalena Anguita Arance, Araceli Salamanca Cuenca, Antonio Jiménez-Velasco, Santiago Osorio Prendes, Marta Santaliestra, María José Lis Chulvi, Juan Carlos Hernández-Boluda, Valentín García-Gutiérrez
Publikováno v:
Scientia
Cancers
Volume 15
Issue 4
Pages: 1045
Cancers
Volume 15
Issue 4
Pages: 1045
Simple Summary After the recent irruption of asciminib into the therapeutic arsenal for chronic myeloid leukemia, real-life data remain scarce to determine which patients may benefit most from this drug. Data on the efficacy of the drug in real-world
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95d62a6253d555f83c73979b06dacbda
https://hdl.handle.net/11351/9705
https://hdl.handle.net/11351/9705
Autor:
Nuria Sánchez-Farías, Ruth Stuckey, Santiago Sánchez-Sosa, María Teresa Gómez-Casares, Cristina Bilbao-Sieyro, Adrián Segura-Díaz, Juan Francisco López-Rodríguez
Publikováno v:
World Journal of Clinical Oncology
Clinical trials have demonstrated that some patients with chronic myeloid leukemia (CML) treated for several years with tyrosine kinase inhibitors (TKIs) who have maintained a molecular response can successfully discontinue treatment without relapsin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9aa43733bb310a8c63a222307dfc982a
https://doi.org/10.5306/wjco.v11.i12.996
https://doi.org/10.5306/wjco.v11.i12.996